Kurzfassung

During the recent decades it has been demonstrated that malignant cells carry epitopes allowing for a specific recognition by the cellular immune system, and antitumor T cell responses were regularly seen in patients. It is now accepted that progressive malignant disease despite the presence of antitumor T cells is not an oxymoron considering the complexity of resistance mechanisms that lead to deficient recruitment and function of immune cells, and that the overcoming of these barriers is a...During the recent decades it has been demonstrated that malignant cells carry epitopes allowing for a specific recognition by the cellular immune system, and antitumor T cell responses were regularly seen in patients. It is now accepted that progressive malignant disease despite the presence of antitumor T cells is not an oxymoron considering the complexity of resistance mechanisms that lead to deficient recruitment and function of immune cells, and that the overcoming of these barriers is a major challenge for cancerimmunotherapy. We would like to study the effects of barriers generated by human leukemia cells to escape T cells using FLT3-ITD as a model antigen. » weiterlesen» einklappen